Drug intelligence / Profile preview

PSB114

Development stage: Phase 2
Lead developer: Sound Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PSB114 (also known as QLP2117) is a glycoengineered monoclonal antibody developed by Sound Biologics that targets C-C chemokine receptor type 8 (CCR8). It is specifically designed to selectively deplete CCR8-positive regulatory T cells (Tregs) within the tumor microenvironment through enhanced antibody-dependent cellular cytotoxicity (ADCC). By reducing the immunosuppressive activity of these Tregs, PSB114 aims to restore and boost anti-tumor immune responses. The drug is currently being evaluated in Phase 1/2 clinical trials for the treatment of various solid tumors, often in combination with immune checkpoint inhibitors to modulate the tumor microenvironment and enhance therapeutic efficacy.

Targets

CCR8

Beyond the preview

Go deeper on PSB114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSB114.

Explore the full profile